Canaccord Genuity Reiterates “Buy” Rating for Sarepta Therapeutic (SRPT)
Sarepta Therapeutic (NASDAQ:SRPT)‘s stock had its “buy” rating restated by equities research analysts at Canaccord Genuity in a research note issued to investors on Thursday, AnalystRatings.Net reports. They currently have a $65.00 price objective on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 39.97% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company reiterated a “positive” rating on shares of Sarepta Therapeutic (NASDAQ:SRPT) in a research note to investors on Monday. Separately, analysts at Piper Jaffray Cos. upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “neutral” rating to an “overweight” rating in a research note to investors on Friday, September 20th. Finally, analysts at Deutsche Bank upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “hold” rating to a “buy” rating in a research note to investors on Friday, September 20th. They now have a $71.00 price target on the stock, up previously from $45.00. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $52.43.
In other Sarepta Therapeutic news, Director M Kathleen Behrens acquired 6,500 shares of Sarepta Therapeutic stock in a transaction dated Monday, September 16th. The stock was purchased at an average cost of $37.04 per share, for a total transaction of $240,760.00. Following the purchase, the director now directly owns 44,166 shares in the company, valued at approximately $1,635,909. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Sarepta Therapeutic (NASDAQ:SRPT) traded up 0.45% on Thursday, hitting $46.65. The stock had a trading volume of 1,581,639 shares. Sarepta Therapeutic has a 52 week low of $14.27 and a 52 week high of $49.61. The stock has a 50-day moving average of $36.16 and a 200-day moving average of $36.5. The company’s market cap is $1.564 billion. Sarepta Therapeutic also was the target of some unusual options trading on Monday. Stock traders acquired 10,913 call options on the stock. This is an increase of 336% compared to the average volume of 2,504 call options.
Sarepta Therapeutic (NASDAQ:SRPT) last announced its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.67) by $0.21. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.08 million. The company’s quarterly revenue was down 73.2% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutic will post $-3.24 earnings per share for the current fiscal year.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.